Radioactive drug takes aim at Hard-to-Treat sarcoma

NCT ID NCT07156565

Recruiting now Disease control Sponsor: Ratio Therapeutics, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jul 16, 2026 · Updated 3 times

Summary

This early-phase trial is testing a radioactive drug called [Ac225]RTX-2358 in 30 adults with advanced soft tissue sarcoma that has come back or stopped responding to prior treatment. The drug is given as an IV injection once every 8 weeks for up to 6 doses. The main goals are to check safety, find the best dose, and see if it can shrink tumors. Participants will also receive a diagnostic imaging agent to help identify tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: A radioactive drug called [Ac225]RTX-2358, given by IV every 8 weeks
What this could lead to: If it works, this could point toward a new treatment option for advanced sarcoma that has stopped responding to other therapies.
What could go wrong: This is an early phase 1 trial with only 30 people, so it is primarily testing safety and dosing. The drug may not shrink tumors or may cause significant side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOFT TISSUE SARCOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Recurrence sarcoma soft tissue sarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOFT TISSUE SARCOMA

Contacts and locations

Show contact details

Locations

Case Western
RECRUITING

Cleveland, Ohio, 44106, United States
MD Anderson Cancer Center
RECRUITING

Houston, Texas, 77230, United States
Mayo Clinic
RECRUITING

Rochester, Minnesota, 55905, United States

Contact Email: •••••@•••••
Memorial Sloane Kettering Cancer Center
RECRUITING

New York, New York, 10065, United States
Princess Margaret Cancer Centre
RECRUITING

Toronto, Ontario, M5G 2M9, Canada
UCLA
RECRUITING

Los Angeles, California, 90095, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.